Aligos Therapeutics, Inc.
ALGS
$10.21
$0.373.76%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -60.16% | -76.29% | -74.60% | -63.40% | -53.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.16% | -76.29% | -74.60% | -63.40% | -53.82% |
| Cost of Revenue | -18.93% | -4.02% | -3.79% | 9.46% | 5.27% |
| Gross Profit | 14.07% | -13.32% | -15.33% | -31.78% | -23.95% |
| SG&A Expenses | -19.01% | -24.37% | -23.63% | -25.38% | -16.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.95% | -9.77% | -9.55% | -1.32% | -1.15% |
| Operating Income | 15.41% | -0.96% | -2.00% | -10.67% | -9.58% |
| Income Before Tax | 2.23% | 46.45% | -50.64% | 5.10% | 7.28% |
| Income Tax Expenses | 63.21% | -55.13% | -58.36% | -68.65% | -73.57% |
| Earnings from Continuing Operations | 2.05% | 46.52% | -49.65% | 5.78% | 7.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.05% | 46.52% | -49.65% | 5.78% | 7.92% |
| EBIT | 15.41% | -0.96% | -2.00% | -10.67% | -9.58% |
| EBITDA | 15.29% | -1.51% | -2.66% | -11.50% | -10.62% |
| EPS Basic | 39.18% | 68.40% | 47.85% | 71.84% | 56.90% |
| Normalized Basic EPS | 38.83% | 67.98% | 47.17% | 71.93% | 56.88% |
| EPS Diluted | 4.14% | 46.02% | 47.85% | 71.84% | 56.91% |
| Normalized Diluted EPS | 37.96% | 67.42% | 47.17% | 71.93% | 56.88% |
| Average Basic Shares Outstanding | 62.14% | 84.13% | 144.38% | 245.67% | 181.16% |
| Average Diluted Shares Outstanding | 63.63% | 86.22% | 144.46% | 245.79% | 181.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |